. Inca, Amiante et mésothéliome pleural malin. France: Collection fiche repère. Institut National du Cancer, 2011.

J. C. Pairon, Amiante et effets sur la santé : une thématique toujours d'actualité, Bull Epidémiol Hebd, vol.3, pp.26-34, 2015.

D. Jean, L. Pimpec-barthes, F. Andujar, P. Gregoire, M. Pairon et al., Thoracic Neoplasia-Mesothelioma, Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms, pp.2690-700, 2014.

D. Jean and M. C. Jaurand, Causes and pathophysiology of malignant pleural mesothelioma, Lung Cancer Management, vol.4, pp.219-248, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02483449

P. Andujar, A. Lacourt, P. Brochard, J. C. Pairon, M. C. Jaurand et al., Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles, J Toxicol Environ Health B Crit Rev, vol.19, pp.151-72, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02478603

A. Lacourt, C. Gramond, S. Audignon, S. Ducamp, J. Fevotte et al., Pleural mesothelioma and occupational coexposure to asbestos, mineral wool, and silica, Am J Respir Crit Care Med, vol.187, pp.977-82, 2013.

X. Dhalluin and A. Scherpereel, Chemotherapy and radiotherapy for mesothelioma, Recent Results Cancer Res, vol.189, pp.127-174, 2011.

I. Opitz, Management of malignant pleural mesothelioma-The European experience, J Thorac Dis, vol.6, pp.238-52, 2014.

P. Astoul, E. Roca, F. Galateau-salle, and A. Scherpereel, Malignant pleural mesothelioma: from the bench to the bedside, Respiration, vol.83, pp.481-93, 2012.

R. A. Stahel, W. Weder, E. Felley-bosco, U. Petrausch, A. Curioni-fontecedro et al., Searching for targets for the systemic therapy of mesothelioma, Ann Oncol, vol.26, pp.1649-60, 2015.

G. Zalcman, J. Mazieres, J. Margery, L. Greillier, C. Audigier-valette et al., Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, vol.387, pp.1405-1419, 2016.

A. Scherpereel, J. Mazieres, L. Greillier, P. Dô, O. Bylicki et al., Second-or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial, J Clin Oncol, vol.35, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01676507

A. N. Husain, T. Colby, N. Ordonez, T. Krausz, R. Attanoos et al., Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.137, pp.647-67, 2013.

D. Jean, J. Daubriac, L. Pimpec-barthes, F. Galateau-salle, F. et al., Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02478588

P. Bertino, M. Carbone, and H. Pass, Chemotherapy of malignant pleural mesothelioma, Expert Opin Pharmacother, vol.10, pp.99-107, 2009.

H. L. Kindler, T. G. Karrison, D. R. Gandara, C. Lu, L. M. Krug et al., doubleblind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma, J Clin Oncol, vol.30, pp.2509-2524, 2012.

P. G. Betta, C. Magnani, T. Bensi, N. F. Trincheri, and S. Orecchia, Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma, Arch Pathol Lab Med, vol.136, pp.253-61, 2012.

S. X. Huang, M. C. Jaurand, D. W. Kamp, J. Whysner, and T. K. Hei, Role of mutagenicity in asbestos fiberinduced carcinogenicity and other diseases, J Toxicol Environ Health B Crit Rev, vol.14, pp.179-245, 2011.

Y. Yoshikawa, M. Emi, T. Hashimoto-tamaoki, M. Ohmuraya, A. Sato et al., High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma, Proc Natl Acad Sci U S A, vol.113, pp.13432-13439, 2016.

D. Jean, E. Thomas, M. E. Renier, A. De-reynies, A. Lecomte et al., Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00531343

A. C. Borczuk, J. Pei, R. N. Taub, B. Levy, O. Nahum et al., Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration, Cancer Biol Ther, vol.2016, pp.1-8

R. Bueno, E. W. Stawiski, L. D. Goldstein, S. Durinck, D. Rienzo et al., Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, vol.48, pp.407-423, 2016.

P. Andujar, J. C. Pairon, A. Renier, A. Descatha, I. Hysi et al., Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma, Mutagenesis, vol.28, pp.323-354, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02478590

J. Fleury-feith, C. Lecomte, A. Renier, M. Matrat, L. Kheuang et al., Hemizygosity of N?2 is associated with increased susceptibility to asbestos-induced peritoneal tumours, Oncogene, vol.22, pp.3799-805, 2003.

D. A. Altomare, C. W. Menges, J. Xu, J. Pei, L. Zhang et al., Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis, PLoS One, vol.6, 2011.

J. Xu, Y. Kadariya, M. Cheung, J. Pei, J. Talarchek et al., Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma, Cancer Res, vol.74, pp.4388-97, 2014.

R. Tranchant, L. Quetel, A. Tallet, C. Meiller, A. Renier et al., Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma, Clin Cancer Res, vol.23, pp.3191-202, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02478604

A. Tallet, J. C. Nault, A. Renier, I. Hysi, F. Galateau-salle et al., Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, vol.33, pp.3748-52, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478602

A. De-reynies, M. C. Jaurand, A. Renier, G. Couchy, I. Hysi et al., Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, vol.20, pp.1323-1357, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478599

K. C. Mcloughlin, A. S. Kaufman, and D. S. Schrump, Targeting the epigenome in malignant pleural mesothelioma, Transl Lung Cancer Res, vol.6, pp.350-65, 2017.

B. C. Christensen, E. A. Houseman, J. J. Godleski, C. J. Marsit, J. L. Longacker et al., Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, vol.69, pp.227-261, 2009.

Y. Goto, K. Shinjo, Y. Kondo, L. Shen, M. Toyota et al., Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma, Cancer Res, vol.69, pp.9073-82, 2009.

G. Reid, MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets, J Thorac Dis, vol.7, pp.1031-1071, 2015.

S. Busacca, S. Germano, D. Cecco, L. Rinaldi, M. Comoglio et al., MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications, Am J Respir Cell Mol Biol, vol.42, pp.312-321, 2010.

C. D. Hoang, D. 'cunha, J. Kratzke, M. G. Casmey, C. E. Frizelle et al., Gene expression profiling identifies matriptase overexpression in malignant mesothelioma, Chest, vol.125, pp.1843-52, 2004.

G. J. Gordon, G. N. Rockwell, R. V. Jensen, J. G. Rheinwald, J. N. Glickman et al., Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling, Am J Pathol, vol.166, pp.1827-1867, 2005.

B. C. Christensen, E. A. Houseman, G. M. Poage, J. J. Godleski, R. Bueno et al., Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma, Cancer Res, vol.70, pp.5686-94, 2010.

N. Mcgranahan and C. Swanton, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer Cell, vol.27, pp.15-26, 2015.

M. Hamasaki, S. Matsumoto, S. Abe, D. Hamatake, T. Kamei et al., Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma, Lung Cancer, vol.99, pp.155-61, 2016.

S. Comertpay, S. Pastorino, M. Tanji, R. Mezzapelle, O. Strianese et al., Evaluation of clonal origin of malignant mesothelioma, J Transl Med, vol.12, p.301, 2014.

N. S. Wang, Anatomy of the pleura, Clin Chest Med, vol.19, pp.229-269, 1998.

K. Kiyotani, J. H. Park, H. Inoue, A. Husain, S. Olugbile et al., Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma, Oncoimmunology, vol.6, p.1278330, 2017.

T. A. Yap, J. G. Aerts, S. Popat, and D. A. Fennell, Novel insights into mesothelioma biology and implications for therapy, Nat Rev Cancer, vol.17, pp.475-88, 2017.

I. M. Shapiro, V. N. Kolev, C. M. Vidal, Y. Kadariya, J. E. Ring et al., Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship, Sci Transl Med, vol.6, pp.237-68, 2014.

T. Kato, T. Sato, K. Yokoi, and Y. Sekido, E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells, Oncogene, vol.36, pp.5522-5553, 2017.

B. Thapa, A. Salcedo, X. Lin, M. Walkiewicz, C. Murone et al., The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma, J Thorac Oncol, vol.12, pp.850-859, 2017.